Life science investing is different from other technology investing. There are hurdles faced in testing and clinical trials that do not have a comparison in the technology silo. Life science companies may need to go through several series of venture or collaboration funding and can travel very different journeys to get to an exit. In addition, within life science, the strategy of the startup company can differ based on how it chooses to navigate the path of product development and commercial marketing. Join Cozen O’Connor and the Philadelphia-Israel Chamber of Commerce for a dynamic discussion on investing followed by a reception to connect with colleagues from the industry.
David Baker, Co-Founder, Vallon Pharmaceuticals